fr   en

Tableaux synoptiques (en anglais)

Parcourir par date
Rechercher par mot clé
Date: 2010-02-05
Biotech partner: Therapure Biopharma (Canada)
Pharma Partner: LFB Biomedicaments (France)
Type of agreement: * manufacturing
Compound: undisclosed plasma proteins including coagulation factors
Nature of the agreement: Therapure Biopharma Inc. and LFB Biomedicaments have announced the signing of a toll manufacturing agreement under which Therapure will manufacture key plasma proteins to support an expansion by LFB into global plasma derived medicinal markets.
Under the terms of the agreement, Therapure will be responsible for the manufacture of two undisclosed major plasma proteins. LFB will remain responsible for global regulatory approvals and marketing of these products. Therapure will retrofit its Health Canada licensed manufacturing facility to accommodate the installation of LFB proprietary technology and
processes necessary to meets its manufacturing obligations.
The companies expect the facility to be completed in 2011. Qualification and validation process, including regulatory batches will be performed in 2012 in order to complete the regulatory approval process in the course of 2013.
Financial terms of the agreement: Financial terms were not disclosed.

Go back to previous page